PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. First Quarter 2020 Financial Results Call

Pacific Biosciences of California, Inc. First Quarter 2020 Financial Results Call

MENLO PARK, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its First Quarter 2020 Financial Results on Wednesday, May 6, 2020, at 4:30pm Eastern Time.

The call will be webcast and may be accessed at Pacific Biosciences’ website at:  .

Date:  May 6, 2020

Time:  4:30pm ET

Listen via Internet: 

Toll-free:  888.366.7247

International:  707.287.9330

Conference ID: 5453089

Replay: 

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at .

Contact:  Pacific Biosciences

Trevin Rard

650.521.8450

EN
27/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

 PRESS RELEASE

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2...

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at . Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the ca...

 PRESS RELEASE

PacBio Announces Major Advances for Revio and Vega to Lower Genome Cos...

PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The advancements center on new SPRQ-Nx sequencing chem...

 PRESS RELEASE

PacBio HiFi Technology Selected as Core Platform for South Korea’s Nat...

PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference Project, a landmark national initiative led by the Korea Disease Co...

 PRESS RELEASE

Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic a...

Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies of healthy aging to date MENLO PARK, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate comprehensive genomic and epigenomic data from as...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch